Single domain shark VNAR antibodies neutralize SARS‐CoV‐2 infection in vitro
Authors:
Open Access
- 12 October 2021
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 35 (11) , e21970
Abstract
Single domain shark variable domain of new antigen receptor (VNAR) antibodies can offer a viable alternative to conventional Ig‐based monoclonal antibodies in treating COVID‐19 disease during the current pandemic. Here we report the identification of neutralizing single domain VNAR antibodies selected against the severe acute respiratory syndrome coronavirus 2 spike protein derived from the Wuhan variant using phage display. We identified 56 unique binding clones that exhibited high affinity and specificity to the spike protein. Of those, 10 showed an ability to block both the spike protein receptor binding domain from the Wuhan variant and the N501Y mutant from interacting with recombinant angiotensin‐converting enzyme 2 (ACE2) receptor in vitro. In addition, three antibody clones retained in vitro blocking activity when the E484K spike protein mutant was used. The inhibitory property of the VNAR antibodies was further confirmed for all 10 antibody clones using ACE2 expressing cells with spike protein from the Wuhan variant. The viral neutralizing potential of the VNAR clones was also confirmed for the 10 antibodies tested using live Wuhan variant virus in in vitro cell infectivity assays. Single domain VNAR antibodies, due to their low complexity, small size, unique epitope recognition, and formatting flexibility, should be a useful adjunct to existing antibody approaches to treat COVID‐19.Keywords
All Related Versions
Funding Information
- Pennsylvania Department of Community and Economic Development (CV19‐VTT)
- Karl-Franzens-Universität Graz (COVID‐19)
This publication has 43 references indexed in Scilit:
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptorNature, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineCellular & Molecular Immunology, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Analysis of the binding loops configuration and surface adaptation of different crystallized single‐domain antibodies in response to various antigensJournal of Molecular Recognition, 2016
- Structural insights and biomedical potential of IgNAR scaffolds from sharksmAbs, 2015
- Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with LysozymeScience, 2004